Replies to post #85752 on Cytodyn Inc (CYDY)

[Black-Ops]

What other Pharma climbed to a 70 billion market cap within , lets guess 3 to 5 years? Who cares, They don't have Leron. Does Gilead have anything close to Leron? Do readers listen to the TV ads about side effects of the drugs approved by the FDA. If you take this your hair falls out shortly after you loose a leg and arm. I laugh about the side effects.

What side effects does Leron have? Nothing. Thinking, thinking. None.

Our market; HIV, All the flue types.

22 types of Cancer. Did I write Cancer? Billions. We, CYDY could be doing 70 Billion in Revenue from all the Cancer, Flu, and HIV in 5 years. 70 billion X 10 = what market cap? 700 Billion or 700$ a share. Yes, I am conservative.

Readers are now thinking. Just maybe.

I have witnessed this kind of return with close to 10 of my largest positions as a broker and a venture cap investor. Think BIG PICTURE.

This is my Big Picture. All investors will have unique Paintings. If an investor wants a buy out? Fine. I hope by that time our cash flow allows a CYDY tender offer at a premium to market price. That removes those with that Pig Picture and up the stock price climbs.

[Scooter McCabe]

HIV market was 30 billion in 2019. Cancer is a 160 billion dollar market.
We expect 9 billion in revenue next year from COVID alone. HIV approval is pending as of October. 10 billion revenue would seem reasonable for mono and combo therapy.

So you have at least 19 billion in revenue coming, with cancer looking promising. So you have a nice profitable story stock company eating up market share with a CEO who won't sell out for less than "triple digits per share." Who isn't going to buy the ticket and take the ride?

[LifeLongLearner]

Don’t forget that the cash flow generated from all of these treatments can be used to buy back shares. That can have a huge impact on driving up the price on the remaining shares.